InspireMD Secures CE Mark Approval for CGuard® Prime EPS, Paving Way for European Launch

Reuters

06-13

InspireMD Secures CE Mark Approval for CGuard® Prime EPS, Paving Way for European Launch

InspireMD Inc., a developer of medical devices for stroke prevention, has announced that it has received CE Mark approval under the European Medical Device Regulation $(MDR.AU)$ for its CGuard® Prime Embolic Prevention System $(EPS)$. This approval is a significant milestone for the company, enabling the commercial launch of CGuard™ Prime EPS across its current CE marked markets in Europe. The CGuard Prime® system, which incorporates user feedback to enhance deliverability and deployment, features a proprietary MicroNet™ mesh designed to reduce embolic events. With this approval, InspireMD is poised to expand its leadership in carotid stenting innovation and plans to launch the platform in the United States later this year, pending FDA approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InspireMD Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-014986), on June 13, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2543868752"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2543868752\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2543868752?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-13 21:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2543868752","market":"fut","top_or_hot":-1,"title":"InspireMD Secures CE Mark Approval for CGuard® Prime EPS, Paving Way for European Launch","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      InspireMD Secures CE Mark Approval for CGuard® Prime EPS, Paving Way for European Launch\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/NSPR\">InspireMD Inc.</a>, a developer of medical devices for stroke prevention, has announced that it has received CE Mark approval under the European Medical Device Regulation <a href=\"https://laohu8.com/S/MDR.AU\">$(MDR.AU)$</a> for its CGuard® Prime Embolic Prevention System <a href=\"https://laohu8.com/S/EPS\">$(EPS)$</a>. This approval is a significant milestone for the company, enabling the commercial launch of CGuard™ Prime EPS across its current CE marked markets in Europe. The CGuard Prime® system, which incorporates user feedback to enhance deliverability and deployment, features a proprietary MicroNet™ mesh designed to reduce embolic events. With this approval, InspireMD is poised to expand its leadership in carotid stenting innovation and plans to launch the platform in the United States later this year, pending FDA approval.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InspireMD Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-014986), on June 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>InspireMD Secures CE Mark Approval for CGuard® Prime EPS, Paving Way for European Launch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInspireMD Secures CE Mark Approval for CGuard® Prime EPS, Paving Way for European Launch\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-13 21:05</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      InspireMD Secures CE Mark Approval for CGuard® Prime EPS, Paving Way for European Launch\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/NSPR\">InspireMD Inc.</a>, a developer of medical devices for stroke prevention, has announced that it has received CE Mark approval under the European Medical Device Regulation <a href=\"https://laohu8.com/S/MDR.AU\">$(MDR.AU)$</a> for its CGuard® Prime Embolic Prevention System <a href=\"https://laohu8.com/S/EPS\">$(EPS)$</a>. This approval is a significant milestone for the company, enabling the commercial launch of CGuard™ Prime EPS across its current CE marked markets in Europe. The CGuard Prime® system, which incorporates user feedback to enhance deliverability and deployment, features a proprietary MicroNet™ mesh designed to reduce embolic events. With this approval, InspireMD is poised to expand its leadership in carotid stenting innovation and plans to launch the platform in the United States later this year, pending FDA approval.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InspireMD Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-014986), on June 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250613:nNDL615fB0:1","article_id":"2543868752","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2543868752","pubTimestamp":1749819955,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"InspireMD Inc., a developer of medical devices for stroke prevention, has announced that it has received CE Mark approval under the European Medical Device Regulation  for its CGuard Prime Embolic Prevention System . This approval is a significant milestone for the company, enabling the commercial launch of CGuard Prime EPS across its current CE marked markets in Europe. The CGuard Prime system, which incorporates user feedback to enhance deliverability and deployment, features a proprietary MicroNet mesh designed to reduce embolic events. With this approval, InspireMD is poised to expand its leadership in carotid stenting innovation and plans to launch the platform in the United States later this year, pending FDA approval.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as fin","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"InspireMD获得CGuard CE标志批准®Prime EPS，为欧洲推出铺平道路","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NSPR":0.9},"content_text":"InspireMD Secures CE Mark Approval for CGuard® Prime EPS, Paving Way for European Launch\n    \n\nInspireMD Inc., a developer of medical devices for stroke prevention, has announced that it has received CE Mark approval under the European Medical Device Regulation $(MDR.AU)$ for its CGuard® Prime Embolic Prevention System $(EPS)$. This approval is a significant milestone for the company, enabling the commercial launch of CGuard™ Prime EPS across its current CE marked markets in Europe. The CGuard Prime® system, which incorporates user feedback to enhance deliverability and deployment, features a proprietary MicroNet™ mesh designed to reduce embolic events. With this approval, InspireMD is poised to expand its leadership in carotid stenting innovation and plans to launch the platform in the United States later this year, pending FDA approval.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InspireMD Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-014986), on June 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,express","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}